Andere Sprachen Soleno Therapeutics, Inc.

Aktien

A3DS0P

US8342033094

SLNO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 28.06.2024			% 5 Tage	% 1. Jan.
40,88 ^USD	-2,08 %		+0,22 %	+1,57 %

28.06.	Soleno Therapeutics reicht bei der FDA einen neuen Zulassungsantrag für die Behandlung des Prader-Willi-Syndroms ein	MT
28.06.	Soleno Therapeutics, Inc. gibt die Einreichung eines neuen Zulassungsantrags für DCCR (Diazoxidcholin) in Tablettenform zur Behandlung des Prader-Willi-Syndroms bei der US-amerikanischen FDA bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Soleno Therapeutics Submits New Drug Application to FDA for Prader-Willi Syndrome Treatment	28.06.
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome	28.06.
Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome	28.06.
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24.06.
Soleno Therapeutics : June 2024 Corporate Presentation	05.06.
Soleno Therapeutics to Join Russell 3000 Index	04.06.
Soleno Therapeutics Set to Join Russell 3000® Index	04.06.
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024	22.05.
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024	22.05.
Soleno Therapeutics to Participate in Upcoming Investor Conferences	22.05.
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community	15.05.
Soleno Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	09.05.
Soleno Therapeutics Prices $138 Million Stock Offering	03.05.
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock	03.05.
Soleno Therapeutics Announces Proposed Public Offering of Common Stock	02.05.
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome	30.04.
Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to Natural History of Prader-Willi Syndrome	30.04.
Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	29.04.
Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline	29.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Soleno Therapeutics, Inc.

Aktien

A3DS0P

US8342033094

SLNO

Andere Sprachen

Filter